Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) is common worldwide. The importance of genetic and epigen- eric changes in etiology and pathogenesis of NAFLD has been increasingly recognized. However, the ex- act mechanism is largely unknown. A large number of single nucleotide polymorphisms (SNPs) related...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 18; no. 45; pp. 6546 - 6551
Main Author Li, Yu-Yuan
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Co., Limited 07.12.2012
Subjects
Online AccessGet full text
ISSN1007-9327
2219-2840
2219-2840
DOI10.3748/wjg.v18.i45.6546

Cover

Abstract Nonalcoholic fatty liver disease (NAFLD) is common worldwide. The importance of genetic and epigen- eric changes in etiology and pathogenesis of NAFLD has been increasingly recognized. However, the ex- act mechanism is largely unknown. A large number of single nucleotide polymorphisms (SNPs) related to NAFLD has been documented by candidate gene studies (CGSs). Among these genes, peroxisome pro- liferatoractivated receptor-γ, adiponectin, leptin and tumor necrosis factor-α were frequently reported. Since the introduction of genome-wide association studies (GWASs), there have been significant advances in our understanding of genomic variations of NAFLD. Patatin- like phospholipase domain containing family member A3 (PNPLA3, SNP rs738409, encoding I148M), also termed adiponutrin, has caught most attention. The evidence that PNPLA3 is associated with increased hepatic fat levels and hepatic inflammation has been validated by a series of studies. Epigenetic modification refers to phenotypic changes caused by an adaptive mechanism unrelated to alteration of primary DNA se- quences. Epigenetic regulation mainly includes microR- NAs (miRs), DNA methylation, histone modifications and ubiquitination, among which miRs are studied most extensively, miRs are small natural single stranded RNA molecules regulating mRNA degradation or translation inhibition, subsequently altering protein expression of target genes. The miR-122, a highly abundant miR ac- counting for nearly 70% of all miRs in the liver, is sig- nificantly under-expressed in NAFLD subjects. Inhibition of miR-122 with an antisense oligonucleotide results in decreased mRNA expression of lipogenJc genes and improvement of liver steatosis. The investigation into epigenetic involvement in NAFLD pathogenesis is just at the beginning and needs to be refined. This review summarizes the roles of genetics and epigenetics in the development of NAFLD. The progress made in this field may provide novel diagnostic biomarkers and therapeu- tic targets for NAFLD management.
AbstractList Nonalcoholic fatty liver disease (NAFLD) is common worldwide. The importance of genetic and epigen- eric changes in etiology and pathogenesis of NAFLD has been increasingly recognized. However, the ex- act mechanism is largely unknown. A large number of single nucleotide polymorphisms (SNPs) related to NAFLD has been documented by candidate gene studies (CGSs). Among these genes, peroxisome pro- liferatoractivated receptor-γ, adiponectin, leptin and tumor necrosis factor-α were frequently reported. Since the introduction of genome-wide association studies (GWASs), there have been significant advances in our understanding of genomic variations of NAFLD. Patatin- like phospholipase domain containing family member A3 (PNPLA3, SNP rs738409, encoding I148M), also termed adiponutrin, has caught most attention. The evidence that PNPLA3 is associated with increased hepatic fat levels and hepatic inflammation has been validated by a series of studies. Epigenetic modification refers to phenotypic changes caused by an adaptive mechanism unrelated to alteration of primary DNA se- quences. Epigenetic regulation mainly includes microR- NAs (miRs), DNA methylation, histone modifications and ubiquitination, among which miRs are studied most extensively, miRs are small natural single stranded RNA molecules regulating mRNA degradation or translation inhibition, subsequently altering protein expression of target genes. The miR-122, a highly abundant miR ac- counting for nearly 70% of all miRs in the liver, is sig- nificantly under-expressed in NAFLD subjects. Inhibition of miR-122 with an antisense oligonucleotide results in decreased mRNA expression of lipogenJc genes and improvement of liver steatosis. The investigation into epigenetic involvement in NAFLD pathogenesis is just at the beginning and needs to be refined. This review summarizes the roles of genetics and epigenetics in the development of NAFLD. The progress made in this field may provide novel diagnostic biomarkers and therapeu- tic targets for NAFLD management.
Nonalcoholic fatty liver disease (NAFLD) is common worldwide. The importance of genetic and epigenetic changes in etiology and pathogenesis of NAFLD has been increasingly recognized. However, the exact mechanism is largely unknown. A large number of single nucleotide polymorphisms (SNPs) related to NAFLD has been documented by candidate gene studies (CGSs). Among these genes, peroxisome proliferatoractivated receptor-γ, adiponectin, leptin and tumor necrosis factor-α were frequently reported. Since the introduction of genome-wide association studies (GWASs), there have been significant advances in our understanding of genomic variations of NAFLD. Patatin-like phospholipase domain containing family member A3 (PNPLA3, SNP rs738409, encoding I148M), also termed adiponutrin, has caught most attention. The evidence that PNPLA3 is associated with increased hepatic fat levels and hepatic inflammation has been validated by a series of studies. Epigenetic modification refers to phenotypic changes caused by an adaptive mechanism unrelated to alteration of primary DNA sequences. Epigenetic regulation mainly includes microRNAs (miRs), DNA methylation, histone modifications and ubiquitination, among which miRs are studied most extensively. miRs are small natural single stranded RNA molecules regulating mRNA degradation or translation inhibition, subsequently altering protein expression of target genes. The miR-122, a highly abundant miR accounting for nearly 70% of all miRs in the liver, is significantly under-expressed in NAFLD subjects. Inhibition of miR-122 with an antisense oligonucleotide results in decreased mRNA expression of lipogenic genes and improvement of liver steatosis. The investigation into epigenetic involvement in NAFLD pathogenesis is just at the beginning and needs to be refined. This review summarizes the roles of genetics and epigenetics in the development of NAFLD. The progress made in this field may provide novel diagnostic biomarkers and therapeutic targets for NAFLD management.
Nonalcoholic fatty liver disease (NAFLD) is common worldwide. The importance of genetic and epigenetic changes in etiology and pathogenesis of NAFLD has been increasingly recognized. However, the exact mechanism is largely unknown. A large number of single nucleotide polymorphisms (SNPs) related to NAFLD has been documented by candidate gene studies (CGSs). Among these genes, peroxisome proliferatoractivated receptor-γ, adiponectin, leptin and tumor necrosis factor-α were frequently reported. Since the introduction of genome-wide association studies (GWASs), there have been significant advances in our understanding of genomic variations of NAFLD. Patatin-like phospholipase domain containing family member A3 (PNPLA3, SNP rs738409, encoding I148M), also termed adiponutrin, has caught most attention. The evidence that PNPLA3 is associated with increased hepatic fat levels and hepatic inflammation has been validated by a series of studies. Epigenetic modification refers to phenotypic changes caused by an adaptive mechanism unrelated to alteration of primary DNA sequences. Epigenetic regulation mainly includes microRNAs (miRs), DNA methylation, histone modifications and ubiquitination, among which miRs are studied most extensively. miRs are small natural single stranded RNA molecules regulating mRNA degradation or translation inhibition, subsequently altering protein expression of target genes. The miR-122, a highly abundant miR accounting for nearly 70% of all miRs in the liver, is significantly under-expressed in NAFLD subjects. Inhibition of miR-122 with an antisense oligonucleotide results in decreased mRNA expression of lipogenic genes and improvement of liver steatosis. The investigation into epigenetic involvement in NAFLD pathogenesis is just at the beginning and needs to be refined. This review summarizes the roles of genetics and epigenetics in the development of NAFLD. The progress made in this field may provide novel diagnostic biomarkers and therapeutic targets for NAFLD management.Nonalcoholic fatty liver disease (NAFLD) is common worldwide. The importance of genetic and epigenetic changes in etiology and pathogenesis of NAFLD has been increasingly recognized. However, the exact mechanism is largely unknown. A large number of single nucleotide polymorphisms (SNPs) related to NAFLD has been documented by candidate gene studies (CGSs). Among these genes, peroxisome proliferatoractivated receptor-γ, adiponectin, leptin and tumor necrosis factor-α were frequently reported. Since the introduction of genome-wide association studies (GWASs), there have been significant advances in our understanding of genomic variations of NAFLD. Patatin-like phospholipase domain containing family member A3 (PNPLA3, SNP rs738409, encoding I148M), also termed adiponutrin, has caught most attention. The evidence that PNPLA3 is associated with increased hepatic fat levels and hepatic inflammation has been validated by a series of studies. Epigenetic modification refers to phenotypic changes caused by an adaptive mechanism unrelated to alteration of primary DNA sequences. Epigenetic regulation mainly includes microRNAs (miRs), DNA methylation, histone modifications and ubiquitination, among which miRs are studied most extensively. miRs are small natural single stranded RNA molecules regulating mRNA degradation or translation inhibition, subsequently altering protein expression of target genes. The miR-122, a highly abundant miR accounting for nearly 70% of all miRs in the liver, is significantly under-expressed in NAFLD subjects. Inhibition of miR-122 with an antisense oligonucleotide results in decreased mRNA expression of lipogenic genes and improvement of liver steatosis. The investigation into epigenetic involvement in NAFLD pathogenesis is just at the beginning and needs to be refined. This review summarizes the roles of genetics and epigenetics in the development of NAFLD. The progress made in this field may provide novel diagnostic biomarkers and therapeutic targets for NAFLD management.
Author Yu-Yuan Li
AuthorAffiliation Department of Gastroenterology and Hepatology, Guangzhou Institute of Clinical Research, Guangzhou First Municipal People's Hospital, Guangzhou Medical College, Guangzhou 510180, Guangdong Province, China
Author_xml – sequence: 1
  givenname: Yu-Yuan
  surname: Li
  fullname: Li, Yu-Yuan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23236228$$D View this record in MEDLINE/PubMed
BookMark eNp9kU1rFDEcxoNU7Lb17knirZdZ8zaZzEWQUqtQ8GLPIZP8ZzYlm2wn2ZF-e7N0XdSDpxDyvJHfBTqLKQJC7yhZ806ojz8fp_VC1dqLdi1bIV-hFWO0b5gS5AytKCFd03PWnaOLnB8JYZy37A06Z5xxyZhaIX0HEYq32ESHYeen43UxszexZOzjGPYQrY8TLhvADhYIabeFWHAacR1kgk2bFKppNKU84-AXmLHzGUyGK_R6NCHD2-N5iR6-3P64-drcf7_7dvP5vrFCqdJIapVwPXVuGEc6QjsOghHay56qgVJHORuMGVxHKbFGDkoBqJ4brkRnoTX8En16yd3thy04W-fNJujd7LdmftbJeP33S_QbPaVF85ZKRmQNuD4GzOlpD7norc8WQjAR0j5rynhP2q7rVZW-_7PrVPL7V6uAvAjsnHKeYTxJKNEHcLqC0xWcruD0AVy1yH8s1hdTfDqs9eF_xg9H4ybF6aliOpUJIQhRkvFffH6tRQ
CitedBy_id crossref_primary_10_3390_ijms16035161
crossref_primary_10_1002_hep_27131
crossref_primary_10_1002_stem_2231
crossref_primary_10_3390_life12060790
crossref_primary_10_3390_nu6083303
crossref_primary_10_1016_j_lfs_2024_122806
crossref_primary_10_4254_wjh_v7_i24_2497
crossref_primary_10_1080_17474124_2020_1736042
crossref_primary_10_3748_wjg_v28_i25_2937
crossref_primary_10_1111_1440_1681_12940
crossref_primary_10_1111_1751_2980_12610
crossref_primary_10_1016_j_cca_2015_05_002
crossref_primary_10_14218_JCTH_2021_00067
crossref_primary_10_3389_fimmu_2022_921765
crossref_primary_10_1016_j_mam_2016_11_008
crossref_primary_10_1152_physiolgenomics_00023_2015
crossref_primary_10_1007_s11901_017_0372_8
crossref_primary_10_1016_j_plefa_2015_04_007
crossref_primary_10_1111_eci_12899
crossref_primary_10_1111_ijpo_234
crossref_primary_10_1016_j_heliyon_2022_e11119
crossref_primary_10_1016_j_hpb_2020_07_011
crossref_primary_10_3748_wjg_v21_i41_11552
crossref_primary_10_1007_s10620_016_4120_7
crossref_primary_10_1186_s41021_022_00246_1
crossref_primary_10_4254_wjh_v6_i8_613
crossref_primary_10_1016_j_gene_2015_09_007
crossref_primary_10_1016_j_jcmgh_2015_05_006
crossref_primary_10_1371_journal_pone_0071391
crossref_primary_10_1186_s12876_016_0557_6
crossref_primary_10_1007_s12072_016_9729_2
crossref_primary_10_2217_epi_2022_0362
crossref_primary_10_1016_j_jaad_2013_10_044
crossref_primary_10_3892_mco_2013_148
crossref_primary_10_1186_s12944_019_1001_z
crossref_primary_10_3109_1354750X_2014_958535
crossref_primary_10_1016_j_metabol_2014_06_016
crossref_primary_10_1111_jdi_12792
crossref_primary_10_1186_s12933_015_0222_3
crossref_primary_10_1155_2018_8635329
crossref_primary_10_3390_nu13051679
crossref_primary_10_1016_j_jnutbio_2013_11_007
crossref_primary_10_3390_jcm5050052
crossref_primary_10_1016_j_ygeno_2013_03_007
crossref_primary_10_1152_ajpgi_00079_2013
crossref_primary_10_3748_wjg_v20_i40_14706
crossref_primary_10_1038_srep23709
crossref_primary_10_1017_S2040174420000124
crossref_primary_10_1186_s12951_018_0391_9
crossref_primary_10_3748_wjg_v21_i4_1099
crossref_primary_10_1016_j_metabol_2015_12_012
crossref_primary_10_1097_MPG_0000000000001053
crossref_primary_10_1136_gutjnl_2015_309456
ContentType Journal Article
Copyright 2012 Baishideng Publishing Group Co., Limited. All rights reserved. 2012
Copyright_xml – notice: 2012 Baishideng Publishing Group Co., Limited. All rights reserved. 2012
DBID 2RA
92L
CQIGP
W91
~WA
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.3748/wjg.v18.i45.6546
DatabaseName 维普_期刊
中文科技期刊数据库-CALIS站点
维普中文期刊数据库
中文科技期刊数据库-医药卫生
中文科技期刊数据库- 镜像站点
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease
EISSN 2219-2840
EndPage 6551
ExternalDocumentID PMC3516206
23236228
10_3748_wjg_v18_i45_6546
44400862
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GroupedDBID ---
123
29R
2B.
2C~
2RA
2WC
36B
53G
5VR
8WL
92F
92I
92L
93N
93R
AAKDD
ACGFO
AENEX
AFUIB
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CHBEP
CIEJG
CQIGP
CS3
CW9
DIK
DU5
E3Z
EBS
EJD
EMB
F5P
FA0
FRP
GX1
HYE
M~E
OK1
P2P
RNS
RPM
SV3
TCJ
TGQ
TR2
W91
WFFXF
XSB
~WA
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c488t-61c84d91ddbff1fe5fb420196918b11d132baabd7110ca6b88ee893a3847ce5a3
ISSN 1007-9327
2219-2840
IngestDate Thu Aug 21 18:21:18 EDT 2025
Fri Jul 11 15:32:42 EDT 2025
Mon Jul 21 05:39:05 EDT 2025
Tue Jul 01 03:21:57 EDT 2025
Thu Apr 24 23:00:00 EDT 2025
Wed Feb 14 10:44:49 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 45
Keywords Nonalcoholic fatty liver disease
MicroRNA
Epigenetic
Methylation
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c488t-61c84d91ddbff1fe5fb420196918b11d132baabd7110ca6b88ee893a3847ce5a3
Notes 14-1219/R
Nonalcoholic fatty liver disease (NAFLD) is common worldwide. The importance of genetic and epigen- eric changes in etiology and pathogenesis of NAFLD has been increasingly recognized. However, the ex- act mechanism is largely unknown. A large number of single nucleotide polymorphisms (SNPs) related to NAFLD has been documented by candidate gene studies (CGSs). Among these genes, peroxisome pro- liferatoractivated receptor-γ, adiponectin, leptin and tumor necrosis factor-α were frequently reported. Since the introduction of genome-wide association studies (GWASs), there have been significant advances in our understanding of genomic variations of NAFLD. Patatin- like phospholipase domain containing family member A3 (PNPLA3, SNP rs738409, encoding I148M), also termed adiponutrin, has caught most attention. The evidence that PNPLA3 is associated with increased hepatic fat levels and hepatic inflammation has been validated by a series of studies. Epigenetic modification refers to phenotypic changes caused by an adaptive mechanism unrelated to alteration of primary DNA se- quences. Epigenetic regulation mainly includes microR- NAs (miRs), DNA methylation, histone modifications and ubiquitination, among which miRs are studied most extensively, miRs are small natural single stranded RNA molecules regulating mRNA degradation or translation inhibition, subsequently altering protein expression of target genes. The miR-122, a highly abundant miR ac- counting for nearly 70% of all miRs in the liver, is sig- nificantly under-expressed in NAFLD subjects. Inhibition of miR-122 with an antisense oligonucleotide results in decreased mRNA expression of lipogenJc genes and improvement of liver steatosis. The investigation into epigenetic involvement in NAFLD pathogenesis is just at the beginning and needs to be refined. This review summarizes the roles of genetics and epigenetics in the development of NAFLD. The progress made in this field may provide novel diagnostic biomarkers and therapeu- tic targets for NAFLD management.
Nonalcoholic fatty liver disease; Epigenetic;MicroRNA; Methylation
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Author contributions: Li YY solely contributed to this paper.
Telephone: +86-20-81048720 Fax: +86-20-81045937
Correspondence to: Yu-Yuan Li, Professor, Department of Gastroenterology and Hepatology, Guangzhou Institute of Clinical Research, Guangzhou First Municipal People’s Hospital, Guangzhou Medical College, Guangzhou 510180, Guangdong Province, China. liyyliyy@tom.com
OpenAccessLink https://www.wjgnet.com/1007-9327/full/v18/i45/6546.htm
PMID 23236228
PQID 1239057798
PQPubID 23479
PageCount 6
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3516206
proquest_miscellaneous_1239057798
pubmed_primary_23236228
crossref_primary_10_3748_wjg_v18_i45_6546
crossref_citationtrail_10_3748_wjg_v18_i45_6546
chongqing_primary_44400862
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2012-12-07
PublicationDateYYYYMMDD 2012-12-07
PublicationDate_xml – month: 12
  year: 2012
  text: 2012-12-07
  day: 07
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle World journal of gastroenterology : WJG
PublicationTitleAlternate World Journal of Gastroenterology
PublicationYear 2012
Publisher Baishideng Publishing Group Co., Limited
Publisher_xml – name: Baishideng Publishing Group Co., Limited
References 21381068 - Hepatology. 2011 Jun;53(6):1883-94
20473581 - Obes Surg. 2010 Dec;20(12):1698-709
20803499 - Hepatology. 2010 Oct;52(4):1281-90
21633658 - World J Gastroenterol. 2011 May 28;17(20):2536-42
19914930 - QJM. 2010 Feb;103(2):71-83
15464424 - Mol Genet Metab. 2004 Sep-Oct;83(1-2):93-102
22093607 - Gastroenterol Hepatol. 2012 Jan;35(1):32-41
18710329 - Metab Syndr Relat Disord. 2008 Sep;6(3):209-14
21037258 - Nucleic Acids Res. 2011 Jan;39(Database issue):D152-7
21538280 - Semin Liver Dis. 2011 May;31(2):128-46
22481692 - Arq Gastroenterol. 2012 Jan-Mar;49(1):89-96
17943122 - Nature. 2007 Oct 18;449(7164):851-61
19487572 - Genes Dev. 2009 Jun 1;23(11):1313-26
16258535 - Nature. 2005 Dec 1;438(7068):685-9
18820647 - Nat Genet. 2008 Dec;40(12):1461-5
22356310 - J Dig Dis. 2012 Mar;13(3):153-60
17999673 - Liver Int. 2008 Mar;28(3):385-92
17522677 - Nature. 2007 May 24;447(7143):433-40
16336439 - J Gastroenterol Hepatol. 2005 Dec;20(12):1825-32
20546964 - J Hepatol. 2010 Aug;53(2):335-8
20648474 - Hepatology. 2010 Oct;52(4):1274-80
20370674 - Curr Pharm Des. 2010 Jun;16(17):1952-7
19780876 - J Gastroenterol Hepatol. 2010 Jan;25(1):156-63
16955276 - J Mol Med (Berl). 2006 Nov;84(11):955-65
17565631 - J Gastroenterol Hepatol. 2007 Jun;22(6):788-93
20684021 - Hepatology. 2010 Sep;52(3):894-903
20492333 - J Gastroenterol Hepatol. 2010 Apr;25(4):772-7
22110478 - Exp Diabetes Res. 2012;2012:716425
21988491 - Scand J Immunol. 2012 Feb;75(2):129-41
19208777 - Eur J Endocrinol. 2009 Apr;160(4):593-602
16255080 - Nature. 2005 Oct 27;437(7063):1299-320
19030170 - Hepatology. 2008 Dec;48(6):1810-20
21497744 - Best Pract Res Clin Gastroenterol. 2011 Apr;25(2):269-80
20027673 - World J Gastroenterol. 2009 Dec 28;15(48):6023-7
19651814 - Diabetes. 2009 Nov;58(11):2616-23
17179747 - RNA Biol. 2004 Jul;1(2):106-13
17554300 - Nature. 2007 Jun 7;447(7145):661-78
20460905 - Dig Dis. 2010;28(1):155-61
18081233 - World J Gastroenterol. 2007 Dec 21;13(47):6419-24
19369657 - N Engl J Med. 2009 Apr 23;360(17):1759-68
21623852 - Aliment Pharmacol Ther. 2011 Aug;34(3):274-85
19323962 - Curr Diab Rep. 2009 Apr;9(2):164-71
19844213 - Int J Obes (Lond). 2010 Jan;34(1):190-4
20890895 - Hepatology. 2010 Dec;52(6):1992-2000
20648472 - Hepatology. 2010 Sep;52(3):904-12
17968429 - Br J Cancer. 2007 Nov 5;97(9):1260-5
19818302 - Clin Liver Dis. 2009 Nov;13(4):511-31
17403181 - Liver Int. 2007 May;27(4):423-33
19738004 - J Lipid Res. 2009 Oct;50(10):2111-6
16459310 - Cell Metab. 2006 Feb;3(2):87-98
15202783 - Clin Chem Lab Med. 2004 May;42(5):487-93
20639500 - J Biomol Screen. 2010 Aug;15(7):798-805
19460359 - Biochem Biophys Res Commun. 2009 Aug 7;385(4):492-6
20708005 - Gastroenterology. 2010 Nov;139(5):1567-76, 1576.e1-6
19450891 - J Hepatol. 2009 Jul;51(1):176-86
19224197 - Diabetologia. 2009 Jun;52(6):1056-60
References_xml – reference: 20460905 - Dig Dis. 2010;28(1):155-61
– reference: 17999673 - Liver Int. 2008 Mar;28(3):385-92
– reference: 20648474 - Hepatology. 2010 Oct;52(4):1274-80
– reference: 18820647 - Nat Genet. 2008 Dec;40(12):1461-5
– reference: 18081233 - World J Gastroenterol. 2007 Dec 21;13(47):6419-24
– reference: 17554300 - Nature. 2007 Jun 7;447(7145):661-78
– reference: 22110478 - Exp Diabetes Res. 2012;2012:716425
– reference: 19780876 - J Gastroenterol Hepatol. 2010 Jan;25(1):156-63
– reference: 20027673 - World J Gastroenterol. 2009 Dec 28;15(48):6023-7
– reference: 17968429 - Br J Cancer. 2007 Nov 5;97(9):1260-5
– reference: 22481692 - Arq Gastroenterol. 2012 Jan-Mar;49(1):89-96
– reference: 21988491 - Scand J Immunol. 2012 Feb;75(2):129-41
– reference: 17179747 - RNA Biol. 2004 Jul;1(2):106-13
– reference: 22093607 - Gastroenterol Hepatol. 2012 Jan;35(1):32-41
– reference: 19208777 - Eur J Endocrinol. 2009 Apr;160(4):593-602
– reference: 21037258 - Nucleic Acids Res. 2011 Jan;39(Database issue):D152-7
– reference: 17403181 - Liver Int. 2007 May;27(4):423-33
– reference: 20684021 - Hepatology. 2010 Sep;52(3):894-903
– reference: 20708005 - Gastroenterology. 2010 Nov;139(5):1567-76, 1576.e1-6
– reference: 21538280 - Semin Liver Dis. 2011 May;31(2):128-46
– reference: 19818302 - Clin Liver Dis. 2009 Nov;13(4):511-31
– reference: 20639500 - J Biomol Screen. 2010 Aug;15(7):798-805
– reference: 19844213 - Int J Obes (Lond). 2010 Jan;34(1):190-4
– reference: 21623852 - Aliment Pharmacol Ther. 2011 Aug;34(3):274-85
– reference: 19738004 - J Lipid Res. 2009 Oct;50(10):2111-6
– reference: 18710329 - Metab Syndr Relat Disord. 2008 Sep;6(3):209-14
– reference: 16955276 - J Mol Med (Berl). 2006 Nov;84(11):955-65
– reference: 17943122 - Nature. 2007 Oct 18;449(7164):851-61
– reference: 19460359 - Biochem Biophys Res Commun. 2009 Aug 7;385(4):492-6
– reference: 16336439 - J Gastroenterol Hepatol. 2005 Dec;20(12):1825-32
– reference: 20648472 - Hepatology. 2010 Sep;52(3):904-12
– reference: 16255080 - Nature. 2005 Oct 27;437(7063):1299-320
– reference: 15464424 - Mol Genet Metab. 2004 Sep-Oct;83(1-2):93-102
– reference: 17522677 - Nature. 2007 May 24;447(7143):433-40
– reference: 20890895 - Hepatology. 2010 Dec;52(6):1992-2000
– reference: 19914930 - QJM. 2010 Feb;103(2):71-83
– reference: 15202783 - Clin Chem Lab Med. 2004 May;42(5):487-93
– reference: 20370674 - Curr Pharm Des. 2010 Jun;16(17):1952-7
– reference: 16459310 - Cell Metab. 2006 Feb;3(2):87-98
– reference: 19651814 - Diabetes. 2009 Nov;58(11):2616-23
– reference: 21633658 - World J Gastroenterol. 2011 May 28;17(20):2536-42
– reference: 21497744 - Best Pract Res Clin Gastroenterol. 2011 Apr;25(2):269-80
– reference: 16258535 - Nature. 2005 Dec 1;438(7068):685-9
– reference: 22356310 - J Dig Dis. 2012 Mar;13(3):153-60
– reference: 20546964 - J Hepatol. 2010 Aug;53(2):335-8
– reference: 19450891 - J Hepatol. 2009 Jul;51(1):176-86
– reference: 20473581 - Obes Surg. 2010 Dec;20(12):1698-709
– reference: 20492333 - J Gastroenterol Hepatol. 2010 Apr;25(4):772-7
– reference: 19369657 - N Engl J Med. 2009 Apr 23;360(17):1759-68
– reference: 20803499 - Hepatology. 2010 Oct;52(4):1281-90
– reference: 19323962 - Curr Diab Rep. 2009 Apr;9(2):164-71
– reference: 21381068 - Hepatology. 2011 Jun;53(6):1883-94
– reference: 19224197 - Diabetologia. 2009 Jun;52(6):1056-60
– reference: 17565631 - J Gastroenterol Hepatol. 2007 Jun;22(6):788-93
– reference: 19030170 - Hepatology. 2008 Dec;48(6):1810-20
– reference: 19487572 - Genes Dev. 2009 Jun 1;23(11):1313-26
SSID ssj0023352
Score 2.327275
SecondaryResourceType review_article
Snippet Nonalcoholic fatty liver disease (NAFLD) is common worldwide. The importance of genetic and epigen- eric changes in etiology and pathogenesis of NAFLD has been...
Nonalcoholic fatty liver disease (NAFLD) is common worldwide. The importance of genetic and epigenetic changes in etiology and pathogenesis of NAFLD has been...
SourceID pubmedcentral
proquest
pubmed
crossref
chongqing
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 6546
SubjectTerms Adiponectin - genetics
Disease Progression
DNA Methylation
Epigenesis, Genetic
Fatty Liver - genetics
Fatty Liver - pathology
Genetic Variation
Genome-Wide Association Study
Humans
Leptin - genetics
MicroRNAs - metabolism
mRNA表达水平
Non-alcoholic Fatty Liver Disease
Phenotype
PPAR gamma - genetics
Protein Structure, Tertiary
Topic Highlight
Tumor Necrosis Factor-alpha - genetics
单核苷酸多态性
肝疾病
肝脏脂肪含量
脂肪肝
表观遗传学
遗传变异
酒精性
Title Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease
URI http://lib.cqvip.com/qk/84123X/201245/44400862.html
https://www.ncbi.nlm.nih.gov/pubmed/23236228
https://www.proquest.com/docview/1239057798
https://pubmed.ncbi.nlm.nih.gov/PMC3516206
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZQuXBBVLxSHjISFw5JceK8jqgCVRUgDq1oT5YdO9tFsLtsk1bi1zPjRzbZBQl6iXazsa3N98UZj2e-IeR1rUzLG3jSZKpVjFtncZ3VWVwortusrJVqbZTv5-L4jJ-c5-cbZ47NLulU0vz6Y17JbVCFc4ArZsn-B7JDp3ACPgO-cASE4fhPGKNmdBBcNSvU1bRfr2H9a8Nb5r4CSUiJ0psIIRvAgVa4rZALjVrZYREJDNOY7Np4w9UF3Yx0JmbyqlsvUdFz7WSc0Lfw9WQo1fXRhglc9PFF7wnofQvMljlxRWidAw0rQGNt09mOUwymq8R5DrbSsDDqAuB2Cf-7U2wf5CP9hIm5VKOXb5E7-dntiR1FcgCNm2-z5JpVyZznSWg5wnn1wwINRiK8ln3O-VRM-8unoyxnRYoi7XfTEsyt4ODxa3RMQbMb5P5fuJ1tHP5we3DUkfYjoTDH5XIx-wn3Z2rg7KxatoNvR9bM6QNy3y9D6DvHqX1yxyweEuH5RIFPdMMnGvhER3yiwCc64hNdtnTMJ2r5RC2fqOfTI3L24f3p0XHsC3DEDczrXVywpuK6ZlqrtmWtyVvFUyuoxCrFmGZZqqRUugQbspGFqipjwP6VGZg8jcll9pjswdDmKaEZYzJty7wumozrSisluUSl0rdG14aziBwMd1CsnNCK4JzbJXdEDsMtFY2XrscKKt8FLGERGwHYCMBGADYCsYnIm6FF6O3v174KKAmYW3HDTC7Msr8SYNXVsJ4p6yoiTxxqQ28B-oiUEzyHC1C3ffrLYn5p9ds9Aw9u3fIZubd5Wp-TvW7dmxdgG3fqpWXzbzruwUo
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genetic+and+epigenetic+variants+influencing+the+development+of+nonalcoholic+fatty+liver+disease&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Li%2C+Yu-Yuan&rft.date=2012-12-07&rft.pub=Baishideng+Publishing+Group+Co.%2C+Limited&rft.issn=1007-9327&rft.volume=18&rft.issue=45&rft.spage=6546&rft.epage=6551&rft_id=info:doi/10.3748%2Fwjg.v18.i45.6546&rft_id=info%3Apmid%2F23236228&rft.externalDocID=PMC3516206
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F84123X%2F84123X.jpg